Francisco Armero Gutiérrez
Private Equity Investor chez Clave Mayor SGEIC SA
Profil
Francisco Armero Gutiérrez is currently a Fund Manager at Clave Mayor SGEIC SA since 2012.
He previously worked as a Director at Traslational Cancer Drugs Pharma SL, HepaCyl Therapeutics SL, and Mevion Technology SL.
Mr. Armero Gutiérrez has a graduate degree from Instituto de Empresa SL, an undergraduate degree from the University of Valladolid, and a graduate degree from Universida de Alcalá de Henares.
Postes actifs de Francisco Armero Gutiérrez
| Sociétés | Poste | Début |
|---|---|---|
Clave Mayor SGEIC SA
 Clave Mayor SGEIC SA Investment ManagersFinance Clave Mayor SGEIC SA (Clave Mayor) is an independent private equity firm founded in 2002. The firm is headquartered in Pamplona with additional offices in Valencia, Spain. | Private Equity Investor | 01/05/2012 |
Anciens postes connus de Francisco Armero Gutiérrez
| Sociétés | Poste | Fin |
|---|---|---|
HepaCyl Therapeutics SL
 HepaCyl Therapeutics SL BiotechnologyHealth Technology HepaCyl Therapeutics SL is a holding company engaged in the design and development of biomedical products for the detection and treatment of hepatitis and cancer. The company was founded on March 5, 2010 and is headquartered in Valladolid, Spain. | Directeur/Membre du Conseil | 01/02/2016 |
Traslational Cancer Drugs Pharma SL
 Traslational Cancer Drugs Pharma SL BiotechnologyHealth Technology Traslational Cancer Drugs Pharma SL engages in the discovery and development of therapeutic solutions for the treatment of cancer. Its TCD-717 choline kinase alpha inhibitor is an intravenously-administered small molecule designed to target cancer cells. It also provides technology in-licensing and out-licensing services. The company was founded by Juan Carlos San Juan on July 29, 2005 and is headquartered in Valladolid, Spain. | Directeur/Membre du Conseil | - |
Mevion Technology SL
 Mevion Technology SL Miscellaneous Commercial ServicesCommercial Services Mevion Technology SL is a holding company engaged in the provision of industrial ionization services, using electron beam accelerators. This technology finds applications in the medical, pharmaceutical, electronics, and aerospace sectors, and allows for product sterilization, sanitation, crosslinking, and depolymerization. It also provides technical consulting, logistics, and microbiological analysis services. The company was founded on September 11, 2009 and is headquartered in Olvega, Spain. | Directeur/Membre du Conseil | - |
Formation de Francisco Armero Gutiérrez
| University of Valladolid | Undergraduate Degree |
| Instituto de Empresa SL | Graduate Degree |
| Universida de Alcalá de Henares | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Clave Mayor SGEIC SA
Clave Mayor SGEIC SA Investment ManagersFinance Clave Mayor SGEIC SA (Clave Mayor) is an independent private equity firm founded in 2002. The firm is headquartered in Pamplona with additional offices in Valencia, Spain. | Finance |
HepaCyl Therapeutics SL
HepaCyl Therapeutics SL BiotechnologyHealth Technology HepaCyl Therapeutics SL is a holding company engaged in the design and development of biomedical products for the detection and treatment of hepatitis and cancer. The company was founded on March 5, 2010 and is headquartered in Valladolid, Spain. | Health Technology |
Mevion Technology SL
Mevion Technology SL Miscellaneous Commercial ServicesCommercial Services Mevion Technology SL is a holding company engaged in the provision of industrial ionization services, using electron beam accelerators. This technology finds applications in the medical, pharmaceutical, electronics, and aerospace sectors, and allows for product sterilization, sanitation, crosslinking, and depolymerization. It also provides technical consulting, logistics, and microbiological analysis services. The company was founded on September 11, 2009 and is headquartered in Olvega, Spain. | Commercial Services |
Traslational Cancer Drugs Pharma SL
Traslational Cancer Drugs Pharma SL BiotechnologyHealth Technology Traslational Cancer Drugs Pharma SL engages in the discovery and development of therapeutic solutions for the treatment of cancer. Its TCD-717 choline kinase alpha inhibitor is an intravenously-administered small molecule designed to target cancer cells. It also provides technology in-licensing and out-licensing services. The company was founded by Juan Carlos San Juan on July 29, 2005 and is headquartered in Valladolid, Spain. | Health Technology |
